Bluebird bio warns of potential bankruptcy as buyout faces another delay
Bluebird bio has warned of possible bankruptcy after buyers Carlyle and SK Capital extended their acquisition deadline yet again due to insufficient shareholder participation, as only about 26% of shares have been tendered—far below the required threshold to complete the deal.
Pharmacists stockpile most common drugs on chance of targeted Trump tariffs
Fearing higher costs and worsening drug shortages from Trump’s proposed tariffs on imported pharmaceuticals, independent pharmacists across the United States are stockpiling common medications to shield their businesses from financial strain, despite deep concerns that the policy could devastate generic drug access and small pharmacy survival.
HIV market expected to reach $32.1bn by 2033 in 7MM
The HIV drug market in the seven major markets is projected to grow modestly to $32.1 billion by 2033, driven by long-acting injectables and novel two-drug regimens, though growth will be tempered by generic competition.
A Chaotic Moment for Pharma Marketing: Q&A with Julius Ramirez
In an interview with Pharmaceutical Executive, Julius Ramirez, SVP, GM, Doceree, describes today’s pharma marketing landscape as chaotic due to fragmented media, rising compliance demands, and shifting healthcare provider (HCP) behaviors—stressing the need for data-driven, personalized engagement strategies and turnkey HCP audiences to deliver relevant, efficient campaigns at scale.
3 Common eCOA Implementation Challenges and How to Solve Them
In an Applied Clinical Trials article, three common challenges in eCOA (electronic clinical outcome assessment) implementation—licensing complexities, post-production changes, and translation/IRB submission delays—are explored alongside practical solutions, highlighting how early engagement, clear planning, and strategic partnerships can help clinical operations teams navigate these hurdles and improve trial efficiency.